MetaCap

Citius Pharmaceuticals (CTXR) vs Lantern Pharma (LTRN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Citius Pharmaceuticals (CTXR) has outperformed Lantern Pharma (LTRN) over the past year, losing 62.0% versus a loss of 80.0%. Over five years, LTRN leads with a -90.9% price change compared with -99.1% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($13.4 million vs $12.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTXR-61.00%LTRN-80.17%
+48%-20%-87%
Oct 8, 20251 yearOct 7, 2026
CTXR-99.04%LTRN-91.76%
+8%-48%-104%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTXR versus LTRN key metrics
MetricCTXRLTRN
Share price$0.4887$0.83
Market cap$13.42M$12.40M
1-day change-2.47%-8.79%
YTD return-37.10%-69.97%
1-year return-61.97%-80.00%
5-year return-99.06%-90.91%
EPS (TTM)$-1.75$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.19$4.68
52-week low$0.469$0.83
Distance from 52-week high-77.68%-82.26%
Analyst consensusnonenone
Avg. price target upside+718.50%+2008.43%
Average volume527.79K180.42K
Shares outstanding27.45M14.94M
Employees2316
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTXR has outperformed LTRN by 18.0 percentage points over the past year.

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Healthcare · Biotechnology · 23 employees

About Lantern Pharma

LTRN stock →

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.

Healthcare · Biotechnology · 16 employees

CTXR vs LTRN FAQ

Which is bigger, Citius Pharmaceuticals or Lantern Pharma?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.42M compared with $12.40M for Lantern Pharma (LTRN).

Which stock has performed better over the past year, CTXR or LTRN?

CTXR returned -61.97% over the past 12 months, compared with -80.00% for LTRN (price return, excluding dividends). Past performance does not predict future results.

Are Citius Pharmaceuticals and Lantern Pharma in the same industry?

Yes. Both are classified in the Biotechnology industry within the Healthcare sector.

More comparisons